The Switzerland-headquartered contract research organization (CRO) has 1,600 employees globally.
Olga Alfonsova, global head of corporate development at PSI told Outsourcing-Pharma.com that the company has been getting many requests from customers to include Asia Pacific countries and South Korea in particular in its “Phase II and III clinical trial geomix.”
PSI provides services to biotech and mid-sized pharma in several areas, including antimicrobial and antifungal infections, oncology, hematology, inflammatory bowel diseases, and neurological conditions, among others, said Alfonsova. “We find that sites in South Korea prove to be excellent contributors to global clinical trials in these therapeutic areas,” she added.
"Seoul is a good place to establish an office with staff monitoring sites all across major clinical trial locations of South Korea,” said Alfonsova.
At the same time, the CRO is also opening an office in Taipei, Taiwan, which Alfonsova said will be announced shortly. The office will be the company’s third in Asia in 2017, following Sydney, Australia and Seoul, South Korea.
“There are many opportunities in Asia Pacific for mid-sized, agile, private CROs such as PSI that are fit to support global clinical trials while all along focusing on on-time project delivery,” said Alfonsova.